Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2018: PRESS-RELEASE: Paris  July17, 2018: World's first: The French Chronic Fatigue Syndrome Association decides to clinically evaluate the ME/CFS pathogenesis model produced by Bio-Modeling Systems

  • 2018: ANNOUNCEMENT: Paris May 28, 2018 Bio-Modeling Systems est heureuse de vous informer sur ses interventions lors des conférences suivantes

  • 2018: ANNOUNCEMENT: Paris June 19-20, 2018: BMSystems invited to the Micorbiotes conference organised by Adebiotech to present its microbiota vision and CADI Discovery programs 

  • 2018: ANNOUNCEMENT: Paris June 14, 2018: BMSystems invited to the Connected Health Conference organised by ANRT to present its Real life data strategy with its "patients & HCP digital pathways" partner Bolero

  • 2018: ANNOUNCEMENT: Paris March 13-14, 2018: BMSystems invited to the Epigentic conference organised by Adebiotech to present its CADI Discovery program EPIGEN-DIAB with the Centrer of excelllence in Eipgenetic in India

  • 2017: PRESS-RELEASE: Paris-November 16, 2017: BMSystems is selected to pitch at the “Translational Neurosciences Conference” organized by “NeurATRIS” and supported by “eartis” the European Infrastructure For Translational Medicine, comprising more than 80 leading European Institutes.

  • 2017: PRESS-RELEASE: Paris-New-York October 4, 2017: BMSystems, with its 14 independently validated successes to date, is selected by the Galien Foundation for the MedStartUp Award 2017 program first step during the US Galien Prize Forum in New-York.
     
  • 2017: ANNOUNCEMENT: Latest news:  Press-release from Hospices Civils de Lyon about phage therapy success with Pherecydes Pharma bacteriophages. Pherecydes-Pharma, is BMSystems’ first therapeutic spin-off.
     

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

CADI™ (Computer Assited Deductive Integretion) Discovery - Value Generation


CADI™ state of the Art first collaborative research programs

  • A collaborative research between the SEPIA laboratory from the François Jacob Institute of biology par of CEA and Bio-Modeling Systems in the field of prion diseases led to a world’s first in vivo validation of the mechanisms of Creutzfeldt-Jakob disease pathogenesis & progression. Two Awards (2009 and 2010).
  • A collaborative research between the SEPIA laboratory from the François Jacob Institute of biology par of CEA and Bio-Modeling Systems in the field of prion diseases led to the filing of the co-owned patent WO201029131 describing a novel therapeutic strategy to treat psychiatric and neurological disorders. This patent is licensed exclusively on a worldwide basis to Theranexus, a CEA spin-off company.
  • A Colllaborative research in the field of biodefence and Multi-resistant bacterias threats has led to  Pherecydes-Pharma (2006): BMSystems’ spin-off, ( novel M.R. anti-bacterial nano-agents biotherapies), two indications:  Skin infections in Phase I/II. & osteo-articular infections.

Technology Developments (know-how, patents)

  • CADI™ Computer-Assisted Deductive Integration, proprietary methodologies and tools.
  • CADI™ Search (data acquisition & mining).
  • CADI™ Architect (data organization & structuring).
  • CADI™ Fiber-N (integrative engine).
  • CADI™ View (model representation & visualization).
  • TAPE Patent: WO/2008/093010- December 2006.
  • AB-ACCUS patent: WO/2008/093009 - December 2006.
  • RIPh patent: PCT/FR2010/050796 – May 2009.
  • CNS copatent: WO/2010/029131 - Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs. September, 2008

Valorisation of our collaborative research:

  • Spin-off (equity, etc,...).

  • Out-Licensing (royalties, etc,...).

  • Consortiums / J.V. (fees, royalties).

Contract Research (fees and possible royalties)

For more details download our Corporate Presentation

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers